Accelerating access to high quality and affordable biosimilars

In several countries, Dr. Reddy’s has significantly expanded access to treatment through the introduction of its biosimilars.

banner1

A biologic, or a biopharmaceutical, is a medicinal product that is manufactured in, or extracted from, a living system (plant, animal or microorganism). Diseases like cancer or autoimmune disorders such as rheumatoid arthritis often require the long term use of biologics. Effective as they are, biologics are also expensive and can place a significant cost burden on both the patient as well as the payer.

At Dr. Reddy’s, we constantly strive to bring the most advanced medicines within the reach of millions around the world. Our continuous efforts to develop and market high quality, equally effective, but significantly more affordable biosimilars* over the past 15 years is a testament to this commitment.

Our biologics development capabilities have made us a leader in the relatively small, but fast-growing biosimilars industry with four biosimilar products marketed in several countries and an extensive pipeline under development. We have proven capabilities that span the therapeutic proteins including glycosylated proteins, monoclonal antibodies and pegylated proteins.

In several markets, where the originator’s biologic is either unavailable or largely unaffordable, Dr. Reddy’s has significantly expanded access to treatment through the introduction of its biosimilars. Since its inception over 400,000 patients have been treated using our biologics products.

In Peru for example, until 2008 the only rituximab available was from the originator. Since its launch in Peru in 2009, Reditux® has helped more than 13,000 patients obtain access to rituximab therapy while significantly easing the burden on the country's healthcare system.

Similarly, in Sri Lanka, Reditux® has helped increase patient access by 30 times since its launch in 2011. Where in FY 11 a mere 10-20 patients per year were being treated, in FY 17, more than 800 patients did.

In Vietnam, patient access has more than doubled since the launch of Reditux®. As against 300 patients in FY14, more than 900 patients benefitted from rituximab treatment in FY 17.

Cresp®, Dr. Reddy’s brand of darbepoetin alfa, was first launched in India in 2010, with the objective of offering a convenient and affordable treatment regimen for anemia management in chronic kidney disease (CKD) patients and as supportive care for patients who develop anemia as a result of myelosuppressive chemotherapy in non-myeloid malignancies. The originator product remains unavailable in India. The availability of Cresp® in India has provided patients and physicians access to the multiple benefits of using darbepoetin alfa such as fewer injections and hence, convenience of use towards anemia management. Over the last 8 years, Cresp® has helped increase patient access to darbepoetin and has been administered to more than 75,000 patients.

In the future, biologics will continue to play an increasingly crucial role in healthcare as new therapies are innovated. At Dr. Reddy’s we will stay focused on our quest to develop high quality and affordable alternatives and take them to patients who need them the most.

*The term biosimilar product is used by the United States Food and Drug Administration (USFDA), and defines biosimilarity to mean that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product.